According to the Gamaleya Center and the Russian Direct Investment Fund, Russia’s Sputnik V vaccine has proven over 90% effective.
“The effectiveness evaluation was performed among the volunteers in accordance with Sputnik Vaccine’s phase III clinical research procedure on the 21 days after the first dose of vaccine or placebo hit the third and ultimate statistically relevant representative control point of the experiment. The data analysis at the final control point in the studies revealed an effectiveness rate of 91.4 percent.”
The Chief Executive Officer of RDIF Kirill Dmitriev confirmed that the data would be used to file demands for Russian vaccine acceleration in other countries. “We also see a high interest in the use of Gamaleya Center vaccine by international pharmaceutical companies, as the use of Sputnik V in conjunction with other vaccines can greatly improve their effectiveness,” it said.
India’s Dr. Reddy’s Labs conducts vaccine clinical trials here while Hetero Biopharma has an association of 100 million vaccine doses. RDIF’s foreign partners are generating global supply, said Russia’s sovereign wealth fund, in India, Brazil, China, South Korea, and other nations.
The final control point study was performed for the effectiveness of the Sputnik V vaccine based on 78 confirmed cases in the placebo group (62 cases) and in the vaccine group 16 cases), according to RDIF.
“100 percent success in extreme coronavirus cases has been shown by the vaccine. In the placebo population there were 20 serious coronavirus infections and no severe cases in the vaccination group,” she added.,” she said.
By 14 December, in the context of the ongoing clinical trials more than 26,000 volunteers were vaccinated at 29 medical centers in Russia. Phase III clinical trials in Belarus, the UAE, Venezuela, and other nations, as well as phase II-III in India, are currently being approved and are currently underway, according to the note.
As part of the inquiry to date, no unexpected adverse effects have been found. Some vaccinated patients have short-term mild adverse events, including injection pain and flu-like symptoms, including weakness, headache and fever.
The cost to international markets of a single dose of Suptnik V is lower than $10, whereas development of the lyophilized (dry) version of the vaccine, which is stored between +2o and +8o Celsius, makes the delivery of the vaccine simpler in international market conditions, the note continued.